Where does Mike Dybbs work?

Mike Dybbs is Director & Co-founder of Kalaris Therapeutics, Inc. and Partner at Samsara BioCapital and Board director at Delfi Diagnostics and Board director at Sutrobio and Board director at Abcuro.

What check size does Mike Dybbs write?

Mike Dybbs typically writes checks of $10M – $100M.

What companies did Mike Dybbs found?

Mike Dybbs founded Kalaris Therapeutics, Inc..

Where did Mike Dybbs go to school?

Mike Dybbs studied at University of California, Berkeley (PhD, Molecular and Cellular Biology); Harvard University (AB, Biochemical Sciences).

Mike Dybbs

InvestorUnicorn founder

Director & Co-founder at Kalaris Therapeutics, Inc. · Partner at Samsara BioCapital · Board director at Delfi Diagnostics · Board director at Sutrobio · Board director at Abcuro

Burlingame, California

Writes $10M – $100M checks · typically $25M

FoundedKalaris Therapeutics, Inc.$1.1B

Find your path to Mike

666 people in our graph share verified history with Mike — schools, employers, funds. One of them is your warm intro.

Chris ChaiunlockedMike: together at Principia Biopharma (2014–2016)

×4Mike: together at Samsara BioCapital

×6Mike: together at New Leaf Venture Partners

Mike: together at Delfi Diagnostics

About

Partner at Samsara since the fund launched in 2017, serving on several portfolio company boards. He previously was a Partner at New Leaf Venture Partners and a Principal at Boston Consulting Group, and holds a PhD in molecular biology from UC Berkeley.

Contact· self-published, not guessed

mike@samsaracap.com

Board director at Delfi Diagnostics

Intro paths

→

In turn, Mike can intro founders to Delfi Diagnostics's investors below.

Delfi Diagnostics's investors · 12

AV8 VenturesPalo Alto · $500K – $10M checks DFJSan Mateo · since 2022 Foresite CapitalWest Hollywood Illumina VenturesFoster City Initiate Venture PartnersPark City · $500K – $2M checks Menlo VenturesSan Francisco · $1M – $20M checks · since 2025 NVIDIASanta Clara Open Field CapitalNew York OrbiMedNew York · $1M – $75M checks OUP (Osage University Partners)Bala Cynwyd · $1M – $20M checks Samsara BioCapitalMenlo Park · since 2025 Windham Capital PartnersNew York · $1M – $5M checks

Co-founders at Delfi Diagnostics

Victor VelculescuFounder and Board Director

Board director at Sutrobio

Intro paths

→

In turn, Mike can intro founders to Sutrobio's investors below.

Sutrobio's investors · 5

Owl Capital Samsara BioCapitalMenlo Park · since 2018 Solasta VenturesBoston SV Health InvestorsLondon · $1M – $20M checks Vida VenturesLos Angeles

Board director at Abcuro

Intro paths

→

In turn, Mike can intro founders to Abcuro's investors below.

Abcuro's investors · 16

abrdn plcEdinburgh · since 2026 Bain Capital Life SciencesBoston · since 2026 Clarus VenturesMenlo Park · since 2025 Eurofarma Venturessince 2026 Foresite CapitalWest Hollywood · since 2026 Mass General Brigham VenturesBoston New Enterprise Associates (NEA)Menlo Park · $200K – $40M checks New Leaf Venture PartnersNew York · since 2026 Pontifax Venture CapitalHerzeliya · $6.3M – $128M checks · since 2023 RA CapitalBoston · since 2026 REDMILESan Francisco · since 2026 Rock Springs CapitalBaltimore · since 2026 Samsara BioCapitalMenlo Park · since 2025 Sanofi VenturesCambridge · $5M checks · since 2020 ShangBay Capital LLCPalo Alto Soleus CapitalGreenwich · since 2026

Co-founders at Abcuro

Steven A. GreenbergChief Scientific Advisor & Co-Founder

Steven A. Greenberg, MDChief Scientific Advisor & Co-Founder

Experience

Samsara BioCapitalPartnercurrent2017 — present
Dimension TherapeuticsBoard of Directors2015 — 2017
Principia BiopharmaBoard of Directors2014 — 2016
Advanced Cell DiagnosticsBoard of Directors2012 — 2016
New Leaf Venture PartnersPartner2009 — 2016
Versartis, Inc.Board of Directors2013 — 2014
The Boston Consulting GroupPrincipal2005 — 2009

Investments

Investor

Advanced Cell DiagnosticsArcellx Claris Bio Dimension Therapeutics IonPathNkarta TherapeuticsPrincipia Biopharma Rayze Bio SutrobioVersartis

Per curated public sources.

What founders say

No founder feedback on Mike Dybbs yet.

Leave your own feedback

Colleagues at Samsara BioCapital

Abe Bassan

Principal at Samsara BioCapital

Alan Eisenberg

Venture Partner at Samsara BioCapital

Andrew Walker

Assistant Controller at Samsara BioCapital

Betsy Santos

Venture Partner, Chief People Officer at Samsara BioCapital

Carolyn Nguyen

Deputy General Counsel at Samsara BioCapital

Clara Dong

Senior Associate at Samsara BioCapital

Connie Su

Senior Fund Accountant at Samsara BioCapital

Cory Freedland

Investor at Samsara BioCapital

Frequently asked questions

Who is Mike Dybbs?: Partner at Samsara since the fund launched in 2017, serving on several portfolio company boards. He previously was a Partner at New Leaf Venture Partners and a Principal at Boston Consulting Group, and holds a PhD in molecular biology from UC Berkeley.
Where does Mike Dybbs work?: Mike Dybbs is Director & Co-founder of Kalaris Therapeutics, Inc. and Partner at Samsara BioCapital and Board director at Delfi Diagnostics and Board director at Sutrobio and Board director at Abcuro.
What check size does Mike Dybbs write?: Mike Dybbs typically writes checks of $10M – $100M.
What companies did Mike Dybbs found?: Mike Dybbs founded Kalaris Therapeutics, Inc..
What companies has Mike Dybbs invested in?: Investments tracked here include Advanced Cell Diagnostics, Arcellx, Claris Bio, Dimension Therapeutics, IonPath, Nkarta Therapeutics, Principia Biopharma, Rayze Bio, Sutrobio, Versartis.
Where did Mike Dybbs go to school?: Mike Dybbs studied at University of California, Berkeley (PhD, Molecular and Cellular Biology); Harvard University (AB, Biochemical Sciences).